AI in Regulatory Intelligence

AI post-approval regulatory monitoring: how to stay ahead of lifecycle obligations

AI post-approval regulatory monitoring: how to stay ahead of lifecycle obligations Approval is not the finish line. It is where the regulatory workload begins. Labelling variations. REMS updates. Post-marketing commitments. PSURs. Regulatory intelligence monitoring across every authorised market. For a biotech with products in 30 or 40 countries, managing the post-approval regulatory landscape is a […]

AI post-approval regulatory monitoring: how to stay ahead of lifecycle obligations Read More »

FDA Converts Tecartus to Full Approval in Relapsed Mantle Cell Lymphoma

AI in Regulatory Intelligence / LuisP

The FDA granted full approval to Tecartus on April 3 2026 for adult patients with relapsed or refractory mantle cell lymphoma based on ZUMA-2 cohort 3 data showing a 91% response rate in BTK-naive patients. Full approval removes payer friction and expands the eligible patient population but increases pressure on CAR-T manufacturing capacity and treatment centre readiness.

FDA Converts Tecartus to Full Approval in Relapsed Mantle Cell Lymphoma Read More »

Dark cinematic 16:9 banner with electric blue regulatory document grid and teal data accents representing AI-assisted pharma regulatory submissions

AI Regulatory Submission Drafting: From Months to Weeks Without Cutting Corners

AI in Regulatory Intelligence / LuisP

AI regulatory submission drafting is cutting variation and NDA dossier preparation time by days per submission. FDA and EMA aligned on joint AI principles in January 2026. This article maps where AI adds value in regulatory workflows, the compliance guardrails that apply, and how teams can build AI drafting capability without creating regulatory risk.

AI Regulatory Submission Drafting: From Months to Weeks Without Cutting Corners Read More »